Reta dose escalation framework — based on Phase 2 titration schedule

Mirroring the Phase 2 dose-escalation protocol from the 2023 NEJM trial. The escalation is critical for GI tolerability based on the published trial data showing dropout patterns at faster ramps.

Not recommending this for any clinical use — this is the research protocol exactly as the published trial structured it.